Public Companies
Lobe Sciences Announces the Expansion of its Patent Portfolio with International Filings
Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBEF), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines…
Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBEF), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that it has expanded its patent portfolio through the filing of international patents in Canada, the United States, Europe and Australia for Methods, Compositions and Devices for Treating Mild Traumatic Brain Injury, Post Traumatic Stress Disorder and Mild Traumatic Brain Injury with Post Traumatic Stress Disorder.
‘This important step is a significant demonstration of our capabilities, particularly as we expand our footprint globally through conducting controlled clinical trials with our patent-pending compound and expanding our patent portfolio internationally. Specifically with the filing of PCT/US2021/028068 in critical international geographies.’
Philip J. Young, Chief Executive Officer of the Company
About Lobe Sciences Ltd
Lobe Sciences is a life sciences company focused on psychedelic medicines. The Company, through collaborations with industry-leading partners, is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness
-
Law & Regulation1 week ago
Tryp Therapeutics, Exopharm merger approved by shareholders
-
LSD1 week ago
The First Wave of Blotter Acid Inspired Trippy Psychedelic Art
-
Psilocybin7 days ago
Psychedelic Underground Celebrated in San Francisco on Bicycle Day Weekend
-
Psychedelics5 days ago
Compass Pathways and Journey Clinical Establish Research Collaboration Agreement To Inform the Training of Healthcare Providers and Delivery Model for COMP360 Psilocybin Treatment, If Approved for Treatment-Resistant Depression
-
Psychedelics5 days ago
Cybin to Participate at the 27th Annual Milken Institute Global Conference
-
Psychedelics4 days ago
Behold! A New Mushroom Emoji Has Arrived!
-
Psychedelics4 days ago
Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression
-
Psychedelics4 days ago
Behold! A New Mushroom Emoji Has Arrived!